Because the vaccine maker may only be paid a very small amount per jab (yet have to supply very high volumes of product), the government essentially agrees to shoulder most of the responsibility should wide-spread but ealier latent side effects be seen. I do not know whether any analogous set of protections exists in Japan, but I suspect something along those lines exists.
In addition, the side effect rate for Merck's vaccine in Japan looks to be around .0006 -- less that 60 per 100,000 doses -- i.e., a very irregular (but possibly still-emerging) set of off-target effects.
So -- I would not expect much movement in either firm's stock price today, based on this. In any event, here is a bit, from The Japan Times story, overnight:
. . . .Minaguchi said the victims will file the suit sometime after June against the central government, GlaxoSmithKlien [sic] PLC, the maker of Cervarix, and Merck Sharp & Dohme Corp., the maker of Gardsil, at four district courts in Tokyo, Nagoya, Osaka and Fukuoka. . . . Out of an estimated 790,000 people given Gardasil 453 experienced side effects. . . .
In April 2013, after the Diet revised the Preventive Vaccination Law, the health ministry began recommending that girls between the ages of 12 and 16 be vaccinated [but the government has since reversed that decision]. . . .
We will (of course) keep an eye on it -- and in the coming days, try to find the answer regarding vaccine courts and shields, on the island. Warm, rainy but now clearing morning -- so goes the Big Shoulders' Spring Thursday. . . smile.
No comments:
Post a Comment